Share capital

DGAP-News: EQS Group AG successfully concludes capital increase - and receives gross issue proceeds of EUR 22.4 million

Retrieved on: 
Wednesday, June 16, 2021
Corporate law, Financial capital, Authorised capital, Share capital, Spółka z ograniczoną odpowiedzialnością

EQS Group AG (ISIN: DE0005494165) successfully completed the capital increase it has announced today and issued a total of 590,000 new registered shares against cash contributions.

Key Points: 
  • EQS Group AG (ISIN: DE0005494165) successfully completed the capital increase it has announced today and issued a total of 590,000 new registered shares against cash contributions.
  • The new shares are issued under a capital increase from authorised capital.
  • According to current plans, this capital increase will be registered in the commercial register on 25 June 2021.
  • After the increase, the company's share capital will rise from EUR 7,882,251.00 by EUR 590,000.00 to EUR 8,472,251.00, where subscription rights of existing shareholders were excluded.

Global Crossing Airlines Provides an Update on FAA Certification and Special Meeting of Shareholders

Retrieved on: 
Friday, June 11, 2021
Equity securities, Stock market, Financial economics, Corporate finance, Finance, Mergers and acquisitions, Corporate law, Non-voting stock, Shareholder, Common stock, Stock, Share capital

Miami, Florida--(Newsfile Corp. - June 11, 2021) - Global Crossing Airlines Group Inc. (TSXV: JET) (OTCQB: JETMF) (the "Company" or "GlobalX") is pleased to provide an update on the FAA Certification process and the Special Meeting of Shareholders scheduled for June 23, 2021, at 9:00 a.m. (Vancouver time) (the "Special Meeting").

Key Points: 
  • Miami, Florida--(Newsfile Corp. - June 11, 2021) - Global Crossing Airlines Group Inc. (TSXV: JET) (OTCQB: JETMF) (the "Company" or "GlobalX") is pleased to provide an update on the FAA Certification process and the Special Meeting of Shareholders scheduled for June 23, 2021, at 9:00 a.m. (Vancouver time) (the "Special Meeting").
  • In addition, there has been progress with new contracts (subject to FAA Certification and DOT approval) and airplane acquisitions.
  • The Company previously announced that it will be holding the Special Meeting to approve a reorganization of its share capital (the "Share Capital Reorganization").
  • A new class of non-voting shares will be created designated as the Class B Non-Voting Common Stock (the "Class B Non-Voting Shares").

IDEX Biometrics: Employee Share Purchase Plan - 3 June 2021

Retrieved on: 
Friday, June 4, 2021
Finance, Money, IDEX, Economy, Employee stock purchase plan, Share capital, Share

The board of directors of IDEX Biometrics ASA has resolved to issue 972,642 ordinary shares at NOK 2.08 per share to employees who participate in the companys Employee Share Purchase Plan (ESPP), which plan was approved by the annual general meeting on 15 May 2020.

Key Points: 
  • The board of directors of IDEX Biometrics ASA has resolved to issue 972,642 ordinary shares at NOK 2.08 per share to employees who participate in the companys Employee Share Purchase Plan (ESPP), which plan was approved by the annual general meeting on 15 May 2020.
  • The participating employees have elected to invest a part of the base salary in ordinary shares in the company.
  • Following the issue, the Company's share capital will be NOK 137,734,306.50 divided into 918,228,710 shares each with a nominal value of NOK 0.15.
  • IDEX discloses transactions by the following primary insiders in IDEX shares ISIN NO0003070609:
    - CEO Vince Graziani acquired 19,984 ordinary shares at NOK 2.08 per share.

SThree: Voting Rights and Capital

Retrieved on: 
Tuesday, June 1, 2021
Stock market, Corporate law, Finance, Financial economics, Money, Corporate finance, Sthree, Issued shares, Issuer, Insider trading, Share capital

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • At the date of this announcement, SThree plc's issued share capital consists of 133,488,709 ordinary shares of 1p each.
  • Currently there are 35,767 shares held in Treasury, and the total number of voting rights in SThree plc is 133,452,942.

Total Voting Rights

Retrieved on: 
Tuesday, June 1, 2021
Corporate finance, Corporate law, Financial economics, Corporations, Finance, Stock market, Equity securities, Issued shares, Common stock, Share capital

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • In conformity with 5.6.1R of the Disclosure Guidance and Transparency Rules, Arix Bioscience plc announces that its total issued share capital at the close of business on 28 May 2021 comprised 135,609,653 Ordinary Shares of 0.001 pence each fully paid.
  • This figure includes 3,592,853 Ordinary Shares which are held in Treasury, leaving a balance of 132,016,800 Ordinary Shares with voting rights.

RUBIS: Share capital decrease by cancellation of own shares

Retrieved on: 
Monday, May 31, 2021
Financial markets, Financial economics, Equity securities, Finance, Corporate finance, Stock market, Preferred stock, Euronext, Share capital, Common stock

Dissemination of a French Regulatory News, transmitted by EQS Group.

Key Points: 
  • Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • The share capital decrease is effective as of May 31, 2021, as indicated in the Euronext notice dated on May 27, 2021.
  • Following this cancellation, the share capital amounts to 126,579,652.50 euros, divided into 101,263,722 shares (101,257,032 ordinary shares and 6,690 preferred shares (with no voting rights)).

DGAP-News: Global Fashion Group S.A.: DISCLOSURE OF THE TOTAL NUMBER OF VOTING RIGHTS AND CAPITAL, IN ACCORDANCE WITH THE LAW AND GRAND-DUCAL REGULATION OF 11 JANUARY 2008 ON TRANSPARENCY REQUIREMENTS FOR ISSUER

Retrieved on: 
Thursday, May 27, 2021
Corporate finance, Financial economics, Equity securities, Finance, Corporations, Stock market, Corporate law, Financial capital, Share capital, Suffrage, Electronic voting, Transparency Directive

Total number of voting rights attached to the shares composing the share capital of the notifying issuer, including the suspended voting rightsii

Key Points: 

Total number of voting rights attached to the shares composing the share capital of the notifying issuer, including the suspended voting rightsii
Total number of voting rights, excluding suspended voting rights (exercisable voting rights) (optional)

Rubis: Results from the capital increase reserved for Group employees

Retrieved on: 
Thursday, May 20, 2021
Financial markets, Financial economics, Stock market, Finance, Equity securities, Corporate finance, Rubis, Preferred stock, Share capital, Dividend, Euronext, Share

b"Dissemination of a French Regulatory News, transmitted by EQS Group.\nThe issuer is solely responsible for the content of this announcement.\nRubis had announced, on February 5, 2021, a capital increase reserved for eligible employees of the companies belonging to the Corporate Savings Plan, Rubis Avenir.

Key Points: 
  • b"Dissemination of a French Regulatory News, transmitted by EQS Group.\nThe issuer is solely responsible for the content of this announcement.\nRubis had announced, on February 5, 2021, a capital increase reserved for eligible employees of the companies belonging to the Corporate Savings Plan, Rubis Avenir.
  • The maximum nominal amount authorized by the shareholders at the June 11th, 2019 meeting was \xe2\x82\xac700,000 (560,000 Rubis shares) from which was deducted the amount of \xe2\x82\xac128,546.25 (102,837 Rubis shares) used for the capital increase reserved for the Group's employees of 2020.\nThe subscription price had been set at \xe2\x82\xac26.35, which, pursuant to Article L 3332-19 of the French Labor Code, represents 70% of the average of the opening rates quoted during the 20 trading days preceding the decision of the Board of Management of January 4, 2021.\nThe subscription period was extended from March 22 to April 9, 2021.\nThe funds invested into Rubis shares through FCPE Rubis Avenir will be available at the end of a 5-year lock-up period, except in the case of an early release.\nAt the end of the subscription, Rubis confirmed that 683 employees, or 66.31% of the eligible employees, thus subscribed to the capital increase, in the amount of \xe2\x82\xac6,999,245.10.\n265,626 new ordinary shares (or 0.26% of outstanding shares) were issued on May 19, 2021.\nThe new shares are eligible for dividends as of January 1, 2021 and they are not entitled to the dividend in respect of the 2020 financial year.
  • They are considered to be of the same rank as existing shares.
  • Their acceptance for trading on the Euronext Paris market was requested as from their issuance, on a second listing line, in comparison with the existing shares.\nAt the end of this transaction, the share capital of Rubis was brought up to \xe2\x82\xac129,872,256.25, divided into 103,891,115 ordinary shares and into 6 690 preferred shares, with a nominal value of \xe2\x82\xac1.25.\n"

Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

Retrieved on: 
Thursday, May 20, 2021
Corporate finance, Zealand Pharma, Warrant, Share capital, Corporations, Companies

The increase is a consequence of the exercise of warrants granted under one of Zealand Pharma\'s employee warrant programs.\nEmployee warrant programs are part of Zealand Pharma\xe2\x80\x99s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma-share at a pre specified price, the exercise price, in specific predefined time periods before expiration.

Key Points: 
  • The increase is a consequence of the exercise of warrants granted under one of Zealand Pharma\'s employee warrant programs.\nEmployee warrant programs are part of Zealand Pharma\xe2\x80\x99s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma-share at a pre specified price, the exercise price, in specific predefined time periods before expiration.
  • Zealand Pharma has only one class of shares.\nThe new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority.
  • Following registration of the new shares, the share capital of Zealand Pharma will be nominal DKK 43,451,842 divided into 43,451,842 shares with a nominal value of DKK 1 each.\nThe amendments to Zealand Pharma\xe2\x80\x99s Articles of Association entailed by the share capital increase have been set out below.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.\n'

DGAP-News: Bestinver announces successful completion of the private placement in Befesa

Retrieved on: 
Tuesday, May 18, 2021
Finance, Financial services, Corporate finance, Banks, Berenberg Bank, Berenberg family, Gossler family, Abengoa, Book building, Bookrunner, Berenberg, Share capital

("Bestinver") announces the successful completion of the sale of 1,702,997 existing ordinary shares (the "Shares") of Befesa, S.A. ("Befesa" or the "Company") by several of its managed funds, representing c. 5.00% of the Company\'s outstanding share capital, by means of a private placement via an accelerated bookbuild offering ("Private Placement"), that was launched yesterday.

Key Points: 
  • ("Bestinver") announces the successful completion of the sale of 1,702,997 existing ordinary shares (the "Shares") of Befesa, S.A. ("Befesa" or the "Company") by several of its managed funds, representing c. 5.00% of the Company\'s outstanding share capital, by means of a private placement via an accelerated bookbuild offering ("Private Placement"), that was launched yesterday.
  • The Befesa shares have been placed at a price of \xe2\x82\xac58.50 per share.
  • Following the successful completion of the Private Placement, Bestinver will no longer hold any shares in Befesa.\nSettlement is expected to take place on 20th May 2021.\nJoh.
  • Berenberg, Gossler & Co. KG acted as Sole Bookrunner on the transaction.\nThe information was submitted for publication by Joh.